Turn Biotechnologies Acquires ARMMs Technology for Enhanced Epigenetic Therapies

Deal News | Mar 27, 2025 | PR Newswire Cision Turn Biotechnologies, Inc.

Turn Biotechnologies, a leader in epigenetic reprogramming, has announced the acquisition of the ARMMs technology, licensed from Harvard University and developed by Vesigen Therapeutics in Cambridge, Massachusetts. This technology is integrated with Turn Biotechnologies' existing eTurna LNP delivery platform to enhance the targeting capabilities of its epigenetic therapies across a wide range of tissues and organs, including the retina, lung, nervous system, liver, and spleen. ARMMs technology facilitates more precise, scalable, and safer delivery of genetic editors, proteins, and RNA-based therapies. It promises potential therapeutic advancements in areas such as ophthalmology, dermatology, and immunotherapy. The ARMMs platform, which utilizes human extracellular vesicles for non-viral delivery, offers significant advantages over current methods, including high biocompatibility and the ability to transport diverse molecular payloads. The acquisition aligns with Turn Biotechnologies’ strategy to accelerate the development of their drug candidates, supported by investments from Bayer Healthcare LLC among others.

Sectors

  • Biotechnology
  • Healthcare

Geography

  • United States – Turn Biotechnologies is based in Mountain View, California, and the ARMMs technology originated from Harvard University in Massachusetts, indicating significant U.S. involvement.

Industry

  • Biotechnology – The article discusses Turn Biotechnologies' acquisition of ARMMs technology, which relates to groundbreaking advancements in biotechnology, particularly in gene-editing and epigenetic therapies.
  • Healthcare – Turn Biotechnologies is working on therapies that could transform healthcare treatments for age-related conditions, incorporating new delivery mechanisms to improve treatment effectiveness.

Financials

    Participants

    NameRoleTypeDescription
    Turn Biotechnologies, Inc.AcquirerCompanyA company pioneering in epigenetic reprogramming, focused on developing novel drug delivery systems for age-related disorders.
    Harvard UniversityLicensorInstitutionThe institution from which the ARMMs delivery technology was licensed by Turn Biotechnologies.
    Vesigen TherapeuticsSellerCompanyA company based in Cambridge, Massachusetts, that developed the ARMMs technology under license from Harvard University.
    Bayer Healthcare LLCInvestorCompanyA leading healthcare company investing in Turn Biotechnologies' innovative developments.
    Morningside Group Ltd.InvestorCompanyAn investment group involved in supporting Turn Biotechnologies' technology advancements.
    Alexandria VenturesInvestorCompanyA venture capital firm investing in the latest innovations in biotechnology including Turn Biotechnologies.
    Anja KrammerCEOPersonThe Chief Executive Officer of Turn Biotechnologies, commenting on the importance of ARMMs technology to the company's mission.